Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-α

Jinsil Seong, Christopher G. Milross, Nancy R. Hunter, Hang C. Shin, Luka Milas

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We studied the combination of tumor necrosis factor (TNF) and paclitaxel. Our aim was to determine whether TNF increases the antitumor efficacy of paclitaxel and if so whether the increase is mediated through the enhancement of apoptosis induction by paclitaxel. Mice bearing 6 mm MCa-K or MCa-4 mammary carcinomas, OCa-I ovarian carcinomas, or HCa-I hepatocarcinomas in their legs were treated with TNF, paclitaxel or their combination. TNF was administered i.p. daily at a dose of 10 μg per mouse for 7 days; paclitaxel at a dose of 40 mg/kg per mouse was given as a single i.v. injection 1 h before the second dose of TNF. Tumor growth delay was used as the endpoint of tumor response to the treatments. The results showed that the combination was either additive or supraadditive; supraadditive action occurred in three of the four tumors tested. The enhancement factors (EFs) were 1.24 for MCa-K, 1.53 for Mca-4, 1.0 for OCa-I and 2.17 for HCa-I. Histological analysis of treated MCa-K tumors revealed that TNF alone did not induce apoptosis of tumor cells, but in the combination it enhanced the apoptotic response to paclitaxel. Thus, TNF increased the antitumor efficacy of paclitaxel by enhancing cellular sensitivity to paclitaxel's induction of apoptosis. The results imply that the combination of TNF and paclitaxel has potential as a treatment for cancer.

Original languageEnglish
Pages (from-to)80-87
Number of pages8
JournalAnti-Cancer Drugs
Volume8
Issue number1
DOIs
Publication statusPublished - 1997 Feb 19

Fingerprint

Paclitaxel
Tumor Necrosis Factor-alpha
Neoplasms
Apoptosis
Leg
Breast Neoplasms
Carcinoma
Injections
Therapeutics
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Cite this

Seong, Jinsil ; Milross, Christopher G. ; Hunter, Nancy R. ; Shin, Hang C. ; Milas, Luka. / Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-α. In: Anti-Cancer Drugs. 1997 ; Vol. 8, No. 1. pp. 80-87.
@article{1e2cbc0895394a60b9a0b9e3784e2f57,
title = "Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-α",
abstract = "We studied the combination of tumor necrosis factor (TNF) and paclitaxel. Our aim was to determine whether TNF increases the antitumor efficacy of paclitaxel and if so whether the increase is mediated through the enhancement of apoptosis induction by paclitaxel. Mice bearing 6 mm MCa-K or MCa-4 mammary carcinomas, OCa-I ovarian carcinomas, or HCa-I hepatocarcinomas in their legs were treated with TNF, paclitaxel or their combination. TNF was administered i.p. daily at a dose of 10 μg per mouse for 7 days; paclitaxel at a dose of 40 mg/kg per mouse was given as a single i.v. injection 1 h before the second dose of TNF. Tumor growth delay was used as the endpoint of tumor response to the treatments. The results showed that the combination was either additive or supraadditive; supraadditive action occurred in three of the four tumors tested. The enhancement factors (EFs) were 1.24 for MCa-K, 1.53 for Mca-4, 1.0 for OCa-I and 2.17 for HCa-I. Histological analysis of treated MCa-K tumors revealed that TNF alone did not induce apoptosis of tumor cells, but in the combination it enhanced the apoptotic response to paclitaxel. Thus, TNF increased the antitumor efficacy of paclitaxel by enhancing cellular sensitivity to paclitaxel's induction of apoptosis. The results imply that the combination of TNF and paclitaxel has potential as a treatment for cancer.",
author = "Jinsil Seong and Milross, {Christopher G.} and Hunter, {Nancy R.} and Shin, {Hang C.} and Luka Milas",
year = "1997",
month = "2",
day = "19",
doi = "10.1097/00001813-199701000-00011",
language = "English",
volume = "8",
pages = "80--87",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-α. / Seong, Jinsil; Milross, Christopher G.; Hunter, Nancy R.; Shin, Hang C.; Milas, Luka.

In: Anti-Cancer Drugs, Vol. 8, No. 1, 19.02.1997, p. 80-87.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-α

AU - Seong, Jinsil

AU - Milross, Christopher G.

AU - Hunter, Nancy R.

AU - Shin, Hang C.

AU - Milas, Luka

PY - 1997/2/19

Y1 - 1997/2/19

N2 - We studied the combination of tumor necrosis factor (TNF) and paclitaxel. Our aim was to determine whether TNF increases the antitumor efficacy of paclitaxel and if so whether the increase is mediated through the enhancement of apoptosis induction by paclitaxel. Mice bearing 6 mm MCa-K or MCa-4 mammary carcinomas, OCa-I ovarian carcinomas, or HCa-I hepatocarcinomas in their legs were treated with TNF, paclitaxel or their combination. TNF was administered i.p. daily at a dose of 10 μg per mouse for 7 days; paclitaxel at a dose of 40 mg/kg per mouse was given as a single i.v. injection 1 h before the second dose of TNF. Tumor growth delay was used as the endpoint of tumor response to the treatments. The results showed that the combination was either additive or supraadditive; supraadditive action occurred in three of the four tumors tested. The enhancement factors (EFs) were 1.24 for MCa-K, 1.53 for Mca-4, 1.0 for OCa-I and 2.17 for HCa-I. Histological analysis of treated MCa-K tumors revealed that TNF alone did not induce apoptosis of tumor cells, but in the combination it enhanced the apoptotic response to paclitaxel. Thus, TNF increased the antitumor efficacy of paclitaxel by enhancing cellular sensitivity to paclitaxel's induction of apoptosis. The results imply that the combination of TNF and paclitaxel has potential as a treatment for cancer.

AB - We studied the combination of tumor necrosis factor (TNF) and paclitaxel. Our aim was to determine whether TNF increases the antitumor efficacy of paclitaxel and if so whether the increase is mediated through the enhancement of apoptosis induction by paclitaxel. Mice bearing 6 mm MCa-K or MCa-4 mammary carcinomas, OCa-I ovarian carcinomas, or HCa-I hepatocarcinomas in their legs were treated with TNF, paclitaxel or their combination. TNF was administered i.p. daily at a dose of 10 μg per mouse for 7 days; paclitaxel at a dose of 40 mg/kg per mouse was given as a single i.v. injection 1 h before the second dose of TNF. Tumor growth delay was used as the endpoint of tumor response to the treatments. The results showed that the combination was either additive or supraadditive; supraadditive action occurred in three of the four tumors tested. The enhancement factors (EFs) were 1.24 for MCa-K, 1.53 for Mca-4, 1.0 for OCa-I and 2.17 for HCa-I. Histological analysis of treated MCa-K tumors revealed that TNF alone did not induce apoptosis of tumor cells, but in the combination it enhanced the apoptotic response to paclitaxel. Thus, TNF increased the antitumor efficacy of paclitaxel by enhancing cellular sensitivity to paclitaxel's induction of apoptosis. The results imply that the combination of TNF and paclitaxel has potential as a treatment for cancer.

UR - http://www.scopus.com/inward/record.url?scp=0031055545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031055545&partnerID=8YFLogxK

U2 - 10.1097/00001813-199701000-00011

DO - 10.1097/00001813-199701000-00011

M3 - Article

C2 - 9147616

AN - SCOPUS:0031055545

VL - 8

SP - 80

EP - 87

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 1

ER -